New Roche -Bristol Myers Partnership Will Leverage PathAI's Platform

Today Roche announced a new collaboration with Bristol Myers Squibb that will use cutting edge digital methods to bring significant improvements in standardization and interpretation of tissue-based assays. This new partnership will leverage Roche's established partnership with PathAI. Through this new collaboration, Roche will integrate a novel PathAI-developed algorithm for biomarker analysis into their digital pathology workflow software. The AI-powered algorithm will be used by Bristol Myers Squibb to analyze clinical trial samples and generate biomarker data. These pathology imaging tools will enable very precise diagnoses that will lead to personalized treatment options for patients with solid tumors.